Journal ArticleDOI
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Roger Stupp,Pierre Yves Dietrich,Sandrine Ostermann Kraljevic,Alessia Pica,Ivan Maillard,Phillipe Maeder,Reto Meuli,Robert C. Janzer,Gianpaolo Pizzolato,Raymond Miralbell,F. Porchet,Luca Regli,Nicolas de Tribolet,René O. Mirimanoff,Serge Leyvraz +14 more
Reads0
Chats0
TLDR
This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.Abstract:
PURPOSE: Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM). This phase II study was performed to determine the safety, tolerability, and efficacy of concomitant radiation plus temozolomide therapy followed by adjuvant temozolomide therapy in patients with newly diagnosed GBM. PATIENTS AND METHODS: Sixty-four patients were enrolled onto this open-label, phase II trial. Temozolomide (75 mg/m2/d × 7 d/wk for 6 weeks) was administered orally concomitant with fractionated radiotherapy (60 Gy total dose: 2 Gy × 5 d/wk for 6 weeks) followed by temozolomide monotherapy (200 mg/m2/d × 5 days, every 28 days for six cycles). The primary end points were safety and tolerability, and the secondary end point was overall survival. RESULTS: Concomitant radiation plus temozolomide therapy was safe and well tolerated. Nonhematologic toxicities were rare and mild to moderate in severity. During t...read more
Citations
More filters
Journal ArticleDOI
CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
Ramon Martinez,Fernando Setien,Christiane Voelter,Sara Casado,María Paz Quesada,Gabriele Schackert,Manel Esteller +6 more
TL;DR: The epigenetic profile of 32 paired tumor samples of relapsed GBM and their corresponding primary neoplasms with special attention to genes involved in the mitochondria-independent apoptotic pathway is analyzed to suggest hypermethylation of the pro-apoptotic CASP8 is a differential feature of GBM relapses.
Journal ArticleDOI
DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
Toshio Hirohata,Kenichiro Asano,Yoshikazu Ogawa,Shingo Takano,Shingo Takano,Kosaku Amano,Osamu Isozaki,Yoshiyasu Iwai,Kiyohiko Sakata,Noriaki Fukuhara,Hiroshi Nishioka,Shozo Yamada,Shingo Fujio,Kazunori Arita,Koji Takano,Atsushi Tominaga,Atsushi Tominaga,Naomi Hizuka,Hidetoshi Ikeda,R. Yoshiyuki Osamura,Shigeyuki Tahara,Shigeyuki Tahara,Yudo Ishii,Takakazu Kawamata,Akira Shimatsu,Akira Teramoto,Akira Teramoto,Akira Matsuno +27 more
TL;DR: This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms, and it is necessary to survey more cases and evaluate multifactor analyses.
Journal ArticleDOI
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
Nicholas Butowski,Susan M. Chang,Larry Junck,Lisa M. DeAngelis,Lauren E. Abrey,Karen Fink,Timothy F. Cloughesy,Kathleen R. Lamborn,Andres M. Salazar,Michael D. Prados +9 more
TL;DR: The results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide.
Journal ArticleDOI
Aldehyde dehydrogenase 1A1—a new mediator of resistance to temozolomide in glioblastoma
Andrea Schäfer,Julian Teufel,Florian Ringel,Marcus Bettstetter,Ingrid Hoepner,Michael Rasper,Jens Gempt,Julia Koeritzer,Friederike Schmidt-Graf,Bernhard Meyer,Christoph P. Beier,Jürgen Schlegel +11 more
TL;DR: ALDH1A1 is a new mediator for resistance of GBM to temozolomide and a reliable predictor of clinical outcome and may serve as a potential target to improve treatment of human GBM.
Journal ArticleDOI
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy
TL;DR: Temozolomide and Gliadel (carmustine wafers) are generally well tolerated due to their limited systemic toxicity and appear particularly well suited for incorporation into multimodal treatment strategies.
References
More filters
Journal ArticleDOI
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial
Walker,Eben Alexander,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Norrell Ha,Owens G,Joseph Ransohoff,Charles B. Wilson,Gehan Ea,Strike Ta +11 more
TL;DR: An analysis of prognostic factors indicates that the initial performance status, age, the use of only a surgical biopsy, parietal location, the presence of seizures, or the involvement of cranial nerves II, III, IV, and VI are all of significance.
Journal ArticleDOI
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Walker,Sylvan B. Green,David P. Byar,Eben Alexander,Batzdorf U,Brooks Wh,William E. Hunt,MacCarty Cs,Mahaley Ms,John Mealey,Owens G,Ransohoff J nd,Robertson Jt,W. R. Shapiro,Smith Kr,Charles B. Wilson,Strike Ta +16 more
TL;DR: It is suggested that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.
Journal ArticleDOI
The new WHO classification of brain tumours.
TL;DR: The new edition of the World Health Organization (WHO) book on ‘Histological Typing of Tumours of the Central Nervous System’ reflects the progress in brain tumour classification which has been achieved since publication of the first edition in 1979.
Journal ArticleDOI
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Henry Brem,Steven Piantadosi,Steven Piantadosi,Peter C. Burger,Michael D. Walker,Robert G. Selker,N. A. Vick,K Black,Michael B. Sisti,Steven Brem,G Mohr,P Muller,R Morawetz,S.C Schold +13 more
TL;DR: Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.
Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. J. Fischbach,C. H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: This study of malignant glioma patients used a non-parametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration and permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more